L
Lori Wood
Researcher at Queen Elizabeth II Health Sciences Centre
Publications - 136
Citations - 5054
Lori Wood is an academic researcher from Queen Elizabeth II Health Sciences Centre. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 30, co-authored 100 publications receiving 4118 citations. Previous affiliations of Lori Wood include Halifax.
Papers
More filters
Journal ArticleDOI
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y.C. Heng,Wanling Xie,Meredith M. Regan,Lauren C. Harshman,Georg A. Bjarnason,Ulka N. Vaishampayan,Mary J. MacKenzie,Lori Wood,Frede Donskov,Min-Han Tan,Sun Young Rha,Neeraj Agarwal,Christian Kollmannsberger,Brian I. Rini,Toni K. Choueiri +14 more
TL;DR: The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis.
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal ArticleDOI
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Daniel Y.C. Heng,J. Connor Wells,Brian I. Rini,Benoit Beuselinck,Jae-Lyun Lee,Jennifer J. Knox,Georg A. Bjarnason,Sumanta K. Pal,Christian Kollmannsberger,Takeshi Yuasa,Sandy Srinivas,Frede Donskov,Aristotelis Bamias,Lori Wood,D. Scott Ernst,Neeraj Agarwal,Ulka N. Vaishampayan,Sun Young Rha,Jenny J. Kim,Toni K. Choueiri +19 more
TL;DR: Most patients benefited from tumor removal, except for those with four or more IMDC risk factors, and CN is beneficial in synchronous mRCC patients treated with targeted therapy, even after adjusting for prognostic factors.
Journal ArticleDOI
Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The surtime randomized clinical trial
Axel Bex,Peter F.A. Mulders,Michael A.S. Jewett,John Wagstaff,Johannes V. Van Thienen,Christian U. Blank,Roland Van Velthoven,M.P. Laguna,Lori Wood,Harm H.H.E. Van Melick,Maureen J.B. Aarts,Jean Baptiste Lattouf,Thomas Powles,Igle J. de Jong,Sylvie Rottey,Bertrand Tombal,Sandrine Marreaud,Sandra Collette,Sandra Collette,Laurence Collette,John B. A. G. Haanen +20 more
TL;DR: This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib and may identify patients with inherent resistance to systemic therapy before planned CN.
Journal ArticleDOI
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Jenny J. Ko,Wanling Xie,Nils Kroeger,Jae-Lyun Lee,Brian I. Rini,Jennifer J. Knox,Georg A. Bjarnason,Sandy Srinivas,Sumanta K. Pal,Takeshi Yuasa,Martin Smoragiewicz,Frede Donskov,Ravindran Kanesvaran,Lori Wood,D. Scott Ernst,Neeraj Agarwal,Ulka N. Vaishampayan,Sun Young Rha,Toni K. Choueiri,Daniel Y.C. Heng +19 more
TL;DR: The IMDC prognostic model in the second-line targeted therapy setting has an improved prognostic performance and is applicable to a more contemporary patient cohort than that of the three-factor MSKCC model.